Complivit Calcium D3 Forte tab chev. 500mg + 400ME # 30 mint

Release form, composition and packaging

Chewable tablets orange 1 tab.

colecalciferol (vit. D3) in the form of granules * 10 μg (400 IU)

calcium carbonate 1.25 g,

-which corresponds to a calcium content of 500 mg

* Granulate composition: colecalciferol, d, l-alpha-tocopherol, medium-chain triglycerides, sucrose, acacia gum, corn starch, calcium phosphate, water.

30 pcs.

- polymer cans (1) - cardboard packs.

60 pcs.

- polymer cans (1) - cardboard packs.

90 pcs.

- polymer cans.

100 pieces.

- polymer cans.

120 pcs.

- polymer cans.

pharmachologic effect

Combined drug, the action of which is due to its constituent components.

It regulates the metabolism of Ca2 + and phosphates, reduces resorption and increases bone density, replenishes the lack of Ca2 + and vitamin D3 in the body, enhances the absorption of Ca2 + in the intestine and phosphate reabsorption in the kidneys, and promotes bone mineralization.

Calcium carbonate is involved in the formation of bone tissue, blood coagulation, in maintaining stable cardiac activity, in the implementation of processes of transmission of nerve impulses.

The use of Ca2 + and vitamin D3 prevents an increase in the production of parathyroid hormone, which is a stimulator of increased bone resorption.

Pharmacokinetics

Vitamin D3 is absorbed in the small intestine.

Ca2 + is absorbed in ionized form in the proximal small intestine through an active, D-vitamin dependent transport mechanism.

Indications for use

- treatment and prevention of Ca2 + and vitamin D3 deficiency:

- osteoporosis: menopausal, senile, steroid", idiopathic, etc. (prevention and addition to specific treatment)

- osteomalacia (associated with impaired mineral metabolism in patients over 45 years old)

- hypocalcemia (including after adherence to diets with refusal to take milk and dairy products)

- with an increased need during pregnancy and lactation, as well as in children over 12 years of age during the period of intensive growth.

Contraindications for use

- hypersensitivity

- hypercalcemia (including as a result of primary or secondary hyperparathyroidism)

- hypercalciuria

- calcium nephrourolithiasis

- hypervitaminosis D

- sarcoidosis

- osteoporosis due to immobilization

- phenylketonuria (contains aspartame)

- pulmonary tuberculosis (active form).

Use with caution in renal failure, benign granulomatosis, during pregnancy, during lactation, while taking glycosides and thiazide diuretics, in childhood (up to 12 years).

Dosage regimen

Inside, chewed or swallowed whole.

Doses for adults and children over 12 years old - 1 tab.

2 times / day, in the morning and in the evening, mainly with meals, or individually, depending on the clinical picture.

Overdose

Symptoms (after taking 200 chewable tablets): thirst and polyuria (as signs of chronic renal failure), decreased appetite, nausea, vomiting, constipation, dizziness, weakness, headache, fainting, coma

with prolonged use: calcification of blood vessels and tissues.

Laboratory indicators in case of overdose: hypercalciuria, hypercalcemia (Ca2 + in plasma about 2.6 mmol).

Treatment: rehydration, "loop" diuretics, GCS, calcitonin, bisphosphonates, Ca2 + restricted diet, hemodialysis.

Side effect

Constipation, flatulence, nausea, stomach pain, diarrhea.

Hypercalcemia and hypercalciuria.

Allergic reactions.

Drug interactions

Reduces the absorption of bisphosphonates, sodium fluoride and tetracyclines (the interval between doses is at least 2-3 hours).

Increases the risk of developing toxicity of cardiac glycosides (monitoring of the ECG and the patient's condition is necessary).

Phenytoin, barbiturates, GCS reduce the effect of vitamin D3, vitamin A - toxicity.

Name ENG

COMPLIVIT CALCIUM D3 FORTE

Clinical and pharmacological group

A drug that regulates the exchange of calcium and phosphorus

ATX code

Multivitamins with micronutrients

Dosage

500mg + 400IU

Structure

calcium carbonate 1.25 g, which corresponds to a calcium content of 500 mg.

colecalciferol (vit. D3) * 0.01 mg (400 IU).

* in the form of a granulate containing colecalciferol - 0.27%, DL -? - tocopherol - 0.0275%, medium-chain triglycerides - 10.7%, sucrose - 36%, acacia gum - 22%, corn starch - 27%, calcium phosphate (E341) - 0.5 %, water - up to 100%).

Excipients: lactose monohydrate (milk sugar) - 333.118 mg, povidone (medium molecular weight polyvinylpyrrolidone, povidone K17) - 68.24 mg, polysorbate 80 - 1.731 mg, potato starch - 18.969 mg, croscarmellose sodium - 50.282 mg, citric acid - 3.325 (E951) 5.95 mg, magnesium stearate 15.75 mg, peppermint leaf oil 2.625 mg.

Indications

treatment and prevention of Ca2 + and vitamin D3 deficiency:

osteoporosis: menopausal, senile, "steroid", idiopathic, etc. (prevention and addition to specific treatment)

osteomalacia (associated with impaired mineral metabolism in patients over 45 years old)

hypocalcemia (including after adhering to diets with refusal to take milk and dairy products)

with increased need during pregnancy and lactation, as well as in children over 12 years of age during the period of intensive growth.

INN / Active ingredient

Calcium carbonate + colecalciferol

Storage conditions and periods

At a temperature not higher than 25 degrees.

Expiration date: 3 years

Contraindications

hypersensitivity

hypercalcemia (including as a result of primary or secondary hyperparathyroidism)

hypercalciuria

calcium nephrourolithiasis

hypervitaminosis D

sarcoidosis

osteoporosis due to immobilization

phenylketonuria (contains aspartame)

pulmonary tuberculosis (active form).

Use with caution in renal failure, benign granulomatosis, during pregnancy, during lactation, while taking glycosides and thiazide diuretics, in childhood (up to 12 years)

Specifications

Category

Vitamin and mineral complexes

Scope of the medicinal product

General

Release form

Tablet

Manufacturer country

Russia

Package quantity, pcs

thirty

Minimum age from

12 years

Way of introduction

Through the mouth

Vacation conditions

Without recipe

Brand name

OTCPharm

The amount of the dosage form in the primary package

30 pcs.

Primary packaging type

Bank

Type of consumer packaging

Pack of cardboard

Pharmaco-therapeutic group

Calcium-phosphorus metabolism regulator

Anatomical and therapeutic characteristics

A12AX Calcium preparations, in combination with other preparations

Dosage form

Chewable tablets, [mint]

The target audience

Children

Expiration date in days

730

Package weight, g

thirty

Mode of application

:

Inside, chewed or swallowed whole.

Doses for adults and children over 12 years old - 1 tablet 2, in the morning and in the evening, mainly with meals, or individually, depending on the clinical picture.

Dosage (volume) of the substance in the preparation

:

In 1 tab.

calcium carbonate 1.25 g, which corresponds to a calcium content of 500 mg colecalciferol (vit.D3) * 0.01 mg (400 IU)

Information on technical characteristics, delivery set, country of manufacture "